Medtronic CEO On The Company's New Valve Product And How Covidien's Integration Is Progressing


27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


Medtronic PLC (NYSE: MDT) on Tuesday got FDA's approval for its CoreValve Evolut R System. Omar Ishrak, Medtronic CEO, was on CNBC recently to discuss about this new valve product from the company. He also discussed the status of Covidien's integration into Medtronic.


CoreValve Evolut R System

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!


"Well we are really excited about this product," Ishrak began. "This is an upgrade to our existing CoreValve transcatheter valve product. It makes the device repositionable and recapturable, which is a first. Makes the procedure much easier and safer and we think we will get much better outcomes as a result of it. So, we are really excited."


Covidien's Integration


On how the integration of Covidien into Medtronic going, Ishrak said, "Well the integration is going very well. We are really pleased with what we see and we look at integration from a perspective of how people are feeling about the new company and we have done a lot of surveys and people from both legacy Medtronic and Covidien teams really are lying with the mission of Medtronic. It's something that Covidien employees are really rallying around as well as Medtronic employees. So, from a overall employee perspective, it's doing extremely well.


"In addition, from a financial perspective we were pleased with the results of our first-quarter that we finished as a joint company, exceeding expectations actually. We have got a value capture plan or an optimization of cost plan that we feel really good about, really good about. And we think, that's even better than what we originally expected and so all in all it's early days, we have got a lot to do. But we are excited and pleased with where we are," Ishrak concluded.


27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


Posted In: CNBCMedia